Nutritional medical therapy in cachexia patient with oesophageal adenocarcinoma metastases on dexamethasone therapy: A case report
Shiela Stefani, Diyah Eka Andayani

Abstract
Gastroesophageal adenocarcinomas have a high risk of brain metastases. Patients with oesophageal cancer often present with symptoms of gastrointestinal (GI) obstruction and bleeding. On the other hand, high-dose steroids are used to suppress brain oedema in cases of brain tumour, resulting in a drastic rise in appetite. Parenteral nutrition appears to reduce the appetite of humans, so it can be used in palliative patients who receive hypocaloric food to combat hunger. A man, 53 years old with intracranial metastasis space-occupying lesions (SOL) from oesophageal adenocarcinoma and cachexia, received 3x10 mg dexamethasone followed by tapering. Acute upper GI bleeding occurred during hospitalisation; thus, enteral feeding was delayed, and intravenous feeding was otherwise given. After two weeks of hospitalisation, we found that there was a decrease in hunger, change in clinical condition, tolerance to food, and functional ability.

Keywords: Oesophageal adenocarcinoma, Cachexia, Nutrition, Brain neoplasm.

Introduction
Oesophageal cancer is the eighth most prevalent cancer of the sixth most common cause of death in the world. Central nervous system (CNS) metastases of gastrointestinal malignancy are uncommon as demonstrated by just 2% of brain metastasis in patients with oesophageal carcinoma.

Oesophageal cancer typically does not develop during early stage. In general, clinical symptoms include odynophagia, dysphagia, and haematemeses-melena. Brain tumours may result in intracranial hypertension marked by reduced consciousness, severe headache, nausea, projectile vomiting, and seizures. High-dose steroid therapy is typically prescribed for patients with brain tumours to alleviate cerebral oedema.

Patients often experience tumour-associated gastrointestinal...
preconditioning for whole-brain radiation and chemotherapy. After an endoscopy-guided NGT insertion, the patient reported being nauseated after a meal, but there was no vomiting, normal appetite, and regular hunger; nevertheless, there was still evidence of melena. During hospitalisation, the patient received 3x10 mg dexamethasone titrated to a dosage of 2x5 mg on day 14. He demonstrated improved consciousness and was eventually prepared for radiation, followed by chemotherapy.

The given nutritional therapy was focused on NGT-based enteral nutrition; nevertheless, there was proof of upper gastrointestinal bleeding during hospitalisation, which causes the patient to fast temporarily. He reported that deprivation of food and parenteral nutrition could help to reduce his hunger. Following improvement in gastrointestinal bleeding, enteral nutrition was given and increased gradually, along with a reduction in parenteral nutrition. Nutritional therapy in this patient was maintained at least 20 kcal/kg/day with a high-protein diet of 1.2 g/kg/day and vitamin B complex supplementation. Once the NGT showed a red or black residue, the patient was put on fasting and 3-chamber parenteral nutrition was given. When the patient deemed fit to start enteral nutrition, the 2-chamber parenteral nutrition was administered. Gradually, the patient no longer felt hunger, his weight remained at 55 kg, and he was able to sit at the hospital on the 14th day.

Discussion

This study identified a 53-year-old man with oesophageal cancer that is consistent with recent findings that the prevalence of oesophageal cancer in men is four times higher than in women, and that the incidence of oesophageal cancer rises with age and current data from Cipto Mangunkusumo Hospital showed that the peak incidence is about the age of 50-53.8,9

Nutritional therapy in palliative patients focuses on patient comfort, preserving nutritional status and increasing quality of life. Nutritional therapy helps to reduce the adverse effects of the treatment and improve the response of patients to cancer therapy.10

During his hospital stay, the patient was given 3x10 mg dexamethasone and was tapered off to a dose of 2x5 mg. Steroid stimulates neuropeptide Y (NPY) expression, an orexigenic hormone, and inhibits (proopiomelanocortin) POMC synthesis, an anorexigenic hormone, all of which act on hypothalamus for appetite regulation.6 The anti-anorexie effect of steroid only lasts for the first 2-4 weeks, and thus can only be used for this purpose for two weeks.

The prescription of 3-8 mg dexamethasone daily for consecutive four days indicated an increased in the appetite of the patient.11 After day 4 of the hospitalization, the patient began to complain of hunger. He received a liquid diet following NGT placement. The patient became nauseated after NGT insertion, presumable due to a sudden loss of obstructed oesophagus so that the food could reach the stomach directly. This problem was handled by small daily feeding with high-nutrient-density foods. In addition, nausea can also be caused by active gastrointestinal bleeding following steroid therapy.

This patient was supposed to receive a minimum of 20 kcal/kg/day healthy balance diet with 1.2g/kg/day protein. Provision of parenteral nutrition appeared to decrease appetite. This is linked to signals from nutrients to the centre of satiety in the hypothalamus. High blood glucose and the insulin levels will increase stimulation of POMC neurons in the arcuate nucleus and neurons in the satiety centre of the hypothalamus in ventromedial and paraventricular nucleus and also will decrease stimulation of NPY neurons in the arcuate nucleus and neurons in the hunger centre of the lateral hypothalamus. Likewise, some amino acids and free fatty acids can increase stimulation of the satiety centre neurons and decrease
stimulation of hunger centre neurons in the hypothalamus.\textsuperscript{12,13}

Energy consumption decreased in this case due to the preparation of bronchoscopy and also because the patient had gastrointestinal bleeding. Nutrition was administrated by increasing gradually the patient's tolerance to the target dietary therapy with target protein intake of 1.2g/kgBB/day as shown in Figure-1. Supplementary parenteral nutrition has been given to the patient to meet his nutritional needs as shown in Figure-2. Based on the guidelines of the European Society for Clinical Nutrition and Metabolism (ESPEN),\textsuperscript{14} parenteral nutrition is recommended when enteral nutrition is not feasible. However, the provision of dietary, medicinal therapy to these patients did not sustain or raise the levels of haemoglobin and albumin.

In palliative patients, a dietary plan may contribute to a lower quality of life, and the presence of ketone in malnutrition can result in euphoric mood and decreased hunger, and pain.\textsuperscript{15} Two weeks after the treatment, the patient showed changes in clinical parameters, tolerance to enteral nutrition, and functional capacity to become a non-ambulatory patient.

**Conclusion**

Palliative care is the treatment of choice for patients with oesophageal cancer inoperable brain metastases. The patients’ convenience is the main concern in palliative care. Feeding is given progressively, according to their tolerance, in order to preserve their nutritional status and functional capacity; however, micronutrient fulfilment must be sought. Small frequent feeding, as well as parenteral nutrition, is recommended to reduce hunger in those receiving corticosteroid therapy.

**Acknowledgement:** None.

**Disclaimer:** None.

**Conflict of Interest:** None.

**Funding Disclosure:** None.

**References**